Physician profile
Asha Thomas
NPI 1568442960
$830.52
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $555 · 2020: $15.00 · 2021: $46.00 · 2022: $214.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $147.98 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $124.13 | 2022 | |
| Amgen INC. | $103.68 | 2019-2020 | |
| Genzyme Corporation | $96.68 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $78.91 | 2019 | |
| Glaxosmithkline, LLC. | $78.60 | 2019-2022 | |
| Horizon Therapeutics Plc | $46.00 | 2021 | |
| Aquestive Therapeutics, INC. | $41.01 | 2019 | |
| Medexus Pharma, INC. | $36.02 | 2019 | |
| Pfizer INC. | $35.62 | 2019 | |
| Aurinia Pharma U.S., INC. | $26.05 | 2022 | |
| Ucb, INC. | $15.84 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asha Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.